Abstract
2002Background: Management of adult low grade gliomas (LGG) remains controversial. Previous results from a phase II clinical trial investigating adjuvant temozolomide (TMZ) as an alternative to radiation demonstrated progression-free survival (PFS) and overall survival (OS) comparable to historical controls receiving radiation alone. Here we present results stratified by newly defined molecular subgroups to determine optimal candidates for adjuvant chemotherapy as a means of delaying or obviating the need for radiation. Methods: 120 patients with newly diagnosed WHO grade II LGGs with gross residual disease after surgical resection were enrolled in a phase II clinical trial. Patients received monthly cycles of TMZ for up to 1 year or until progression, and were monitored with serial MRI at baseline and every 2 months during treatment. 97 patients with available tissue were grouped into molecular subtype based on 1p19q codeletion and IDH1 status (1p19q codel: 1p19q codeleted/IDH1 mutated; IDH1mut: 1p19q in...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
